Learn About D-Minus Hemolytic Uremic Syndrome

What is the definition of D-Minus Hemolytic Uremic Syndrome?
D-minus (diarrhea negative) hemolytic uremic syndrome is an extremely rare, progressive genetic disease characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia).
Save information for later
Sign Up
What are the symptoms of D-Minus Hemolytic Uremic Syndrome?
Symptoms of D-minus hemolytic uremic syndrome may include malaise, fatigue, irritability, lethargy, decreased urine, paleness, scattered bruising, gastrointestinal bleeding, high blood pressure, headaches, double vision, facial paralysis, stroke, seizures, coma, fluid in the lungs, enlarged heart, and kidney failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Minus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous nutrition and fluid replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplant.
Who are the top D-Minus Hemolytic Uremic Syndrome Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest D-Minus Hemolytic Uremic Syndrome Clinical Trials?
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Summary: This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

What are the Latest Advances for D-Minus Hemolytic Uremic Syndrome?
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review.
The frontline of TMA management.
Tired of the same old research?
Check Latest Advances
Oxaliplatin-induced thrombotic microangiopathy: a case report.